J&J’s RIPTAC Drug JNJ-6143 Posts 77% PSA Response in Phase 1 at ESMO 2026

Johnson & Johnson’s oral RIPTAC molecule JNJ-6143 cut prostate-specific antigen (PSA) levels by at least half in 77% of evaluable patients at 50 mg in phase 1 data presented at ESMO 2026, a year after the 59% early signal that preceded its $3.05 billion Halda buy.

A gate lifts open to reveal a wide empty space as a single geometric token crosses the threshold, with tiny silhouettes standing behind it.

ONCOLOGY · CLINICAL DATA · OCTOBER 31, 2026 · UNITED STATES

Johnson & Johnson’s oral prostate cancer candidate JNJ-6143 cut prostate-specific antigen (PSA) levels by at least half in 77% of PSA-evaluable patients at the 50 mg dose, according to phase 1 data the company released Oct. 25, after phase 1 data were presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

JNJ-6143, formerly known as HLD-0915, is the first molecule from the regulated induced proximity targeting chimera (RIPTAC) platform that J&J gained by buying Halda Therapeutics. According to J&J, 48% of patients at 50 mg had PSA reductions of at least 90%, and 75% of patients with measurable disease (12 of 16) had a confirmed complete or partial response under Response Evaluation Criteria in Solid Tumors (RECIST). J&J said 38 patients received the 50 mg dose; Urology Times reports the PSA rates were calculated on 31 PSA-evaluable patients in that cohort (24 of 31 for PSA50, a decline of at least 50%).

77%

77% of PSA-evaluable patients at the 50 mg dose had a confirmed PSA reduction of at least 50%, per J&J’s ESMO 2026 release and Urology Times.

From a 22-patient signal to a dose-selection readout

The new data follow the first human results, which MD Anderson Cancer Center reported on Oct. 24, 2025, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, a meeting of the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer. Then, 59% of 22 patients who completed at least two cycles had a PSA50 response. J&J agreed to buy Halda for $3.05 billion in cash on Nov. 17, 2025, weeks after that readout, according to Reuters, and completed the deal in December 2025.

The ESMO population is described by J&J as patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), also known as metastatic castration-resistant prostate cancer (mCRPC), whose disease progressed after one or more androgen receptor pathway inhibitors. They had received a median of four prior therapies, including chemotherapy and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy. Reported imaging response differs by data point: pharmaphorum and Urology Times cite 69%, which Urology Times specifies as 11 of 16 at the Sept. 21 data cutoff; Urology Times says one patient converted to a confirmed partial response afterward, raising the rate to 75% (12 of 16), the figure J&J reports.

How the mechanism differs

J&J describes the molecule as a “dual-protein lock” that binds the androgen receptor, highly expressed in prostate cancer cells, to BRD4 (bromodomain-containing protein 4), a protein essential for cell survival, to disrupt cancer cell function and trigger cell death. That matters commercially because J&J’s marketed prostate drugs, Zytiga, Erleada, and Akeega, act at least partly through the androgen receptor pathway, and BioPharma Dive reported J&J sees Halda’s approach as a way to address resistance to those drugs. At 50 mg, the most common treatment-related adverse events were elevated cholesterol (18%), nausea (16%), and elevated triglycerides (16%); one patient (3%) discontinued because of adverse events.

“These early results provide an encouraging foundation for its continued development and our broader exploration of the RIPTAC platform across multiple cancer types,” said Yusri Elsayed, J&J’s global therapeutic area head for oncology.

Who gains, who is exposed

The most direct comparison is Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a PSMA-directed radioligand therapy. Its first-quarter 2026 sales of $642 million rose 70% at constant currencies, Fierce Pharma reported, and Chief Executive Officer Vas Narasimhan reiterated a $5 billion peak sales goal. JNJ-6143’s trial allowed prior radioligand therapy, and nearly half (46%) of the 50 mg cohort had received it, per Urology Times, so for many patients the drug is being tested after, not against, Pluvicto. Eli Lilly, which agreed in 2023 to buy POINT Biopharma for about $1.4 billion to gain PSMA-targeted radioligand candidates for mCRPC, has a stake in the same treatment sequence. Bayer, whose Nubeqa competes with Erleada, lost its bid in April 2026 for a preliminary injunction against J&J’s survival advertising claims, Reuters reported.

The caveat is size and endpoint. These are uncontrolled phase 1 results with a median follow-up of 5.6 months, and PSA and imaging response do not establish survival benefit.

What to Watch

  1. Enrollment and first readouts from the phase 2 study (NCT07832292) at 50 mg once daily in metastatic prostate cancer
  2. Duration of response and survival data as follow-up matures beyond 5.6 months
  3. Whether J&J moves other RIPTAC candidates into the clinic, which pharmaphorum reports include breast and lung cancer programs

The signal for J&J is that the Halda thesis survived its first larger test: activity held up as the program moved from a 22-patient snapshot to a dose-selection cohort. Whether that becomes a franchise depends on randomized data that do not yet exist.

JNJ-6143 · Phase 1 Results at 50 mg (ESMO 2026)

Metric Value
Patients treated at 50 mg 38
Confirmed PSA50 (≥50% decline) 77% (24 of 31 PSA-evaluable)
Confirmed PSA90 (≥90% decline) 48% (15 of 31 PSA-evaluable)
Confirmed RECIST response 75% (12 of 16), per J&J; 69% (11 of 16) at data cutoff
Median prior therapies (all doses) 4
Median follow-up 5.6 months
Discontinuation due to adverse events 1 patient (3%)
Oct. 2025 first data (PSA50) 59% (n=22)

Sources: J&J (Oct. 25, 2026), Urology Times, pharmaphorum, MD Anderson (Oct. 24, 2025)

Why this is relevant

Patients

The trial enrolled men with metastatic prostate cancer that progressed after androgen receptor pathway inhibitors, with a median of four prior therapies. Responses are early and the drug is investigational.

Industry

The readout is the first major clinical return on J&J’s $3.05 billion Halda purchase and positions an investigational, non-radioligand oral candidate in an mCRPC treatment sequence where Novartis and Lilly have invested in radioligand therapy.

Payers

PSA and imaging response are not survival endpoints. Payers will have little to assess until phase 2 and later randomized data report.

Regulators

J&J has selected 50 mg once daily for further development, including phase 2 study NCT07832292; no regulatory filing has been announced.

THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Sources: J&J: Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143 · Urology Times: Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC · pharmaphorum: ESMO26: Halda buy delivers a win for J&J in prostate cancer · MD Anderson: New oral therapy shows early signs of safety and effectiveness · Reuters: J&J expands cancer portfolio with $3.05 billion Halda buy · BioPharma Dive: J&J adds to pharma’s M&A spree with $3B buyout of startup Halda · Fierce Pharma: Novartis stands by $5B Pluvicto goal despite European regulatory setback · Lilly: Lilly to acquire POINT Biopharma · Reuters: US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related